Product Description
a new generation broad-spectrum intravenous cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Ceftobiprole exhibits potent in vitro activity against a number of Gram-positive and Gram-negative pathogens associated with hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP). (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25117196/)
Mechanisms of Action: PBP Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Colombia | France
Approved Indications: None
Known Adverse Events: None
Company: Basilea Pharmaceutica
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Bulgaria, Colombia, Estonia, Georgia, Germany, Greece, Israel, Italy, Latvia, Lithuania, Mexico, Panama, Poland, Russia, Serbia, Slovakia, South Africa, Spain, Turkey, Ukraine, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Bacteremia|Neonatal Sepsis|Sepsis|Staphylococcal Infections
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BPR-PIP-003 | P3 |
Recruiting |
Neonatal Sepsis |
2024-12-01 |
56% |
| 2022-001837-35 | P3 |
Active, not recruiting |
Sepsis |
2024-02-19 |
|
| 2017-001699-43 | P3 |
Completed |
Bacteremia |
2022-03-11 |
|
| BPR-CS-009 | P3 |
Completed |
Staphylococcal Infections|Bacteremia |
2022-03-11 |